# Alpha Teknova, Inc.: overview TKNO · Nasdaq · CIK 1850902 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tkno.md) · [Financials](/companies/tkno/financials.md) · [Filings](/companies/tkno/filings.md) · [Insiders](/companies/tkno/insiders.md) Latest reported revenue: [$12.2m](/filings/0001193125-26-338178.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338178). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.6](/filings/0001193125-25-272321.md) | [9.3 d](/filings/0001850902-26-000002.md) | [9.8](/filings/0001850902-26-000008.md) | [10.3](/filings/0001193125-26-338178.md) | [10.5](/filings/0001193125-25-272321.md) | [10.0 d](/filings/0001850902-26-000002.md) | [11.1](/filings/0001850902-26-000008.md) | [12.2](/filings/0001193125-26-338178.md) | | Gross margin | % | [0.9%](/filings/0001193125-25-272321.md) | [23.0% d](/filings/0001850902-26-000002.md) | [30.7%](/filings/0001850902-26-000008.md) | [38.7%](/filings/0001193125-26-338178.md) | [30.7%](/filings/0001193125-25-272321.md) | [32.5% d](/filings/0001850902-26-000002.md) | [34.2%](/filings/0001850902-26-000008.md) | [40.1%](/filings/0001193125-26-338178.md) | | Operating margin | % | [(77.6%)](/filings/0001193125-25-272321.md) | [(60.7%) d](/filings/0001850902-26-000002.md) | [(50.7%)](/filings/0001850902-26-000008.md) | [(32.9%)](/filings/0001193125-26-338178.md) | [(38.4%)](/filings/0001193125-25-272321.md) | [(46.2%) d](/filings/0001850902-26-000002.md) | [(38.8%)](/filings/0001850902-26-000008.md) | [(23.7%)](/filings/0001193125-26-338178.md) | | Net margin | % | [(79.0%)](/filings/0001193125-25-272321.md) | [(61.7%) d](/filings/0001850902-26-000002.md) | [(47.4%)](/filings/0001850902-26-000008.md) | [(34.7%)](/filings/0001193125-26-338178.md) | [(41.0%)](/filings/0001193125-25-272321.md) | [(47.7%) d](/filings/0001850902-26-000002.md) | [(41.1%)](/filings/0001850902-26-000008.md) | [(26.0%)](/filings/0001193125-26-338178.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001193125-25-272321.md) | not reported | [(0.09)](/filings/0001850902-26-000008.md) | [(0.07)](/filings/0001193125-26-338178.md) | [(0.08)](/filings/0001193125-25-272321.md) | not reported | [(0.08)](/filings/0001850902-26-000008.md) | [(0.06)](/filings/0001193125-26-338178.md) | | Free cash flow | $m | [(2.4) d](/filings/0001193125-25-272321.md) | [(1.5) d](/filings/0001850902-26-000002.md) | [(4.3)](/filings/0001850902-26-000008.md) | [(2.3) d](/filings/0001193125-26-338178.md) | [(2.4) d](/filings/0001193125-25-272321.md) | [(0.8) d](/filings/0001850902-26-000002.md) | [(3.6)](/filings/0001850902-26-000008.md) | [(0.6) d](/filings/0001193125-26-338178.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [36.9](/filings/0000950170-23-010926.md) | [41.4](/filings/0000950170-24-036624.md) | [36.7](/filings/0000950170-25-035705.md) | [37.7](/filings/0001850902-26-000002.md) | [40.5](/filings/0001850902-26-000002.md) | | Gross margin | % | [47.8%](/filings/0000950170-23-010926.md) | [42.2%](/filings/0000950170-24-036624.md) | [28.1%](/filings/0000950170-25-035705.md) | [19.2%](/filings/0001850902-26-000002.md) | [33.2%](/filings/0001850902-26-000002.md) | | Operating margin | % | [(32.5%)](/filings/0000950170-23-010926.md) | [(119.9%)](/filings/0000950170-24-036624.md) | [(96.9%)](/filings/0000950170-25-035705.md) | [(69.3%)](/filings/0001850902-26-000002.md) | [(41.9%)](/filings/0001850902-26-000002.md) | | Net margin | % | [(26.6%)](/filings/0000950170-23-010926.md) | [(114.6%)](/filings/0000950170-24-036624.md) | [(100.3%)](/filings/0000950170-25-035705.md) | [(70.9%)](/filings/0001850902-26-000002.md) | [(42.6%)](/filings/0001850902-26-000002.md) | | Diluted EPS | $ per share | [(0.61)](/filings/0000950170-23-010926.md) | [(1.69)](/filings/0000950170-24-036624.md) | [(1.16)](/filings/0000950170-25-035705.md) | [(0.57)](/filings/0001850902-26-000002.md) | [(0.32)](/filings/0001850902-26-000002.md) | | Free cash flow | $m | [(28.9)](/filings/0000950170-23-010926.md) | [(55.5)](/filings/0000950170-24-036624.md) | [(26.7)](/filings/0000950170-25-035705.md) | [(13.5)](/filings/0001850902-26-000002.md) | [(9.8)](/filings/0001850902-26-000002.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tkno/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $9.4m | 1,661,395 | | Added +592,233 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.2m | 1,614,045 | | Added +1,172,166 | | [Roubaix Capital, LLC](/funds/1769700.md) | 2026-06-30 | $9.0m | 1,579,404 | | Reduced −302,951 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.0m | 879,786 | | Added +163,012 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.6m | 631,967 | | Added +306,804 | | [Conestoga Capital Advisors, LLC](/funds/1163744.md) | 2026-06-30 | $1.8m | 314,554 | | Reduced −2,530 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.8m | 311,818 | | Added +3,945 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $1.5m | 255,760 | | Added +27,474 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $977.1k | 172,017 | | Added +53,578 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $936.5k | 164,885 | | Added +9,796 | ## Recent filings [All 220 filings](/companies/tkno/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 20:41 ET | [8-K](/filings/0001193125-26-427930.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-427930 | | 2026-08-06 | 20:26 ET | [10-Q](/filings/0001193125-26-338178.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338178 | | 2026-08-05 | 20:06 ET | [8-K](/filings/0001193125-26-335059.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335059 | | 2026-06-01 | 21:22 ET | [8-K](/filings/0001850902-26-000011.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001850902-26-000011 | | 2026-05-07 | 20:13 ET | [10-Q](/filings/0001850902-26-000008.md) | Quarterly report, period 2026-03-31 | 0001850902-26-000008 | | 2026-05-06 | 20:11 ET | [8-K](/filings/0001850902-26-000007.md) | 2.02 Results of operations; 5.05 Item not in the standard list; 9.01 Financial statements and exhibits | 0001850902-26-000007 | | 2026-04-21 | 21:22 ET | [DEF 14A](/filings/0001193125-26-167248.md) | Proxy statement, period 2026-04-21 | 0001193125-26-167248 | | 2026-03-02 | 22:10 ET | [10-K](/filings/0001850902-26-000002.md) | Annual report, period 2025-12-31 | 0001850902-26-000002 | | 2026-02-26 | 21:08 ET | [8-K](/filings/0001193125-26-076592.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076592 | | 2025-11-07 | 21:06 ET | [10-Q](/filings/0001193125-25-272321.md) | Quarterly report, period 2025-09-30 | 0001193125-25-272321 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001850902-26-000002.md), filed Mar 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1850902 - Tickers: TKNO - Exchange: Nasdaq - SIC code: 2835 In Vitro & In Vivo Diagnostic Substances - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.